For people with moderate to severe Crohn's disease, the first weeks of a new biologic drug have usually meant trips to an infusion center. On Oct. 23, the US Food and Drug Administration approved a way to skip that step. Adults can now start AbbVie's Skyrizi (risankizumab-rzaa) at home, using an on-body injector, according to the company and several medical news reports.

The approval changes how treatment begins, not what the drug is. The trial behind it also shows how large the benefit was and where it was smaller.

What the FDA Approved

The new regimen is a subcutaneous induction dose of 720 mg at weeks 0, 2, 4 and 8, delivered by an on-body injector pack, according to Investing.com's report on AbbVie's announcement. Patients then continue with the same device every eight weeks during maintenance. The existing intravenous induction, 600 mg at weeks 0, 4 and 8, stays available, per a summary of the label.

Skyrizi is an interleukin-23 inhibitor, a drug that blocks a signaling protein involved in intestinal inflammation. It was already approved for Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. A concurrent label change also leaves pretreatment tuberculosis testing to clinical judgment across all of its approved uses.

What the AFFIRM Trial Showed

The approval rests on AFFIRM, a phase 3 trial that randomized 274 adults 2 to 1 to subcutaneous risankizumab or placebo. About 65% of participants had previously failed another advanced therapy, according to reports of the data. At week 12, clinical remission, defined as a Crohn's Disease Activity Index score below 150, occurred in 56% of treated patients versus 30% on placebo. Endoscopic response, a measure of visible improvement in the intestinal lining, was 43% versus 15%. Both primary endpoints were statistically significant.

The safety profile matched what is known from intravenous Skyrizi in Crohn's disease, and no new risks were identified, the company said.

Who Benefited Most

The results differ by patient history. Among participants who had never failed an advanced therapy, 74% reached clinical remission at week 12 on subcutaneous risankizumab versus 27% on placebo, Credence Research reported from the trial data. That compares with 56% in the full group, which implies that those who had already tried and failed other advanced drugs did less well, though the sources I reviewed did not report that subgroup's rate.

That is a common pattern in Crohn's disease. It matters for doctors choosing a first drug and for patients whose earlier medicines stopped working.

At the American College of Gastroenterology meeting in Nashville this month, the company reported week 24 data. Among patients who responded at week 12 and continued on Skyrizi, 35.8% had endoscopic remission, compared with 9.1% on placebo, per the same report.

Convenience and Open Questions

Moving induction from the infusion chair to the home is a convenience gain. It avoids scheduling infusions and travel, and it lets people start treatment once they are trained to use the device. The sources I reviewed do not say what it will cost, how insurers will cover it or how training will work in practice.

There are limits to what AFFIRM can say. The trial compared the subcutaneous regimen with placebo, not with the intravenous induction, so it does not show that the two are equally effective. The placebo remission rate of 30% is substantial, which is typical in Crohn's trials and a reminder that some improvement happens without active treatment. And the data come from the manufacturer's trial and presentations. I did not see the full paper or the FDA label.

Why It Matters

Making treatment easier to start is a theme across medicine. Blogerroom reported that long-acting HIV injections beat daily pills in African teens, another case where how a drug is delivered shapes whether people can use it. It also follows the pattern of the FDA's approval of Hibsago for hepatitis B, where the benefit for some patients came with clear limits for others.

My view: the real test for the new regimen will not be the trial numbers but how many patients who would otherwise face delays in getting an infusion slot are able to start treatment quickly. That is a question that registries and insurers can answer, and the trial cannot.

What to Watch Next

AbbVie says the subcutaneous induction regimen is also under review by the European Medicines Agency, where Skyrizi is already approved for Crohn's disease with intravenous induction. Watch for that decision, and for real-world data showing remission rates outside a trial.

People with Crohn's disease should discuss treatment choices, including how and where to start, with their gastroenterologist. This article is general information, not medical advice.